16.78
-1.93%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangxi LiuYao Group Co
Its shares trade on Shanghai under the ticker 603368.SS. It has been listed since 4 December 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥20.93bn and net income of CN¥709.5m. At that date it held total assets of CN¥21.34bn and shareholders' equity of CN¥7.83bn.
Guangxi LiuYao Group Co., Ltd. engages in the wholesale and retail business of medicines and medical equipment. The company is headquartered in Liuzhou, Guangxi. The company went IPO on 2014-12-04. The firm is mainly engaged in three businesses. The pharmaceutical wholesale business mainly distributes pharmaceutical products to medical and health institutions at all levels, pharmaceutical distribution enterprises and chain pharmacies. The pharmaceutical retail business provides sales and health services of various pharmaceutical products, medical devices and other pharmaceutical products to individual consumers through terminal pharmacies. The pharmaceutical industry business is mainly engaged in the production and research and development of pharmaceuticals and medical devices. The firm is also engaged in supply chain value-added services, pharmaceutical Internet services, terminal health services, etc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 4 Dec 2014
- Employees
- 5,162
- Website
- lzyy.cn ↗
Leadership
Pay as last reported
- Mr. Chaoyang ZhuChairman of the Board, President, since 2017CN¥620,000
- Mr. Xiangxing ZengChief Financial Officer, Vice President
- Ms. Wenjie ShenVice President, Secretary of the Board, since 2023CN¥380,000
- Ms. Chunxue TangVice President, Director, since 2023CN¥544,000
- Mr. Xianhua ZhuVice President, Director, since 2021CN¥480,000
- Mr. Zhen LiangVice President
- Mr. Xianrong TangVice President, since 2023CN¥411,000
- Mr. Junxiong XiaoVice PresidentCN¥402,000
- Mr. Hong ChenDirector, since 2024CN¥431,400
- Yanmao HuangIndependent Director
- Nianyi MaIndependent Director
- Ms. Jianhong TaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company employs 5,162 full-time staff members.
- It operates a comprehensive wholesale and retail business model.
- The firm engages in pharmaceutical production and research.
Weaknesses
- The source description is explicitly treated as untrusted.
- Specific financial metrics are not provided in the text.
- Market share data is absent from the given facts.
Opportunities
- The firm provides pharmaceutical Internet services.
- Supply chain value-added services are currently offered.
- Terminal health services represent an active business area.
Threats
- The company operates in the regulated health care sector.
- Competitors distribute products to medical institutions.
- Chain pharmacies are part of the distribution network.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.